However, the therapeutic applicability of HER2-targeted therapy is limited, as only 15-30% of gastric cancer patients express HER2 positivity, leaving a substantial portion of patients without effective treatment options (6, 7). The gene discussed is ERBB2; the disease is gastric cancer.